ArticleMedicine2015
Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses.
Article in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 154 citations in OpenAlex.
- The Role of Autoimmune Diseases in the Development of Aortic Aneurysms.Reviews in cardiovascular medicine · 2026Review
- Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.EULAR rheumatology open · 2026Article
- Observational
- The clinical features, pathological findings, and risk factors of intracardiac thrombus in Behçet's syndrome.Clinical rheumatology · 2026Article
- Non-pulmonary arterial involvement in Behçet's disease: a multicenter retrospective case series.Turkish journal of medical sciences · 2026Observational
- Towards a basis for vascular versus intestinal phenotype differences; East Meets West in Behcet's disease.Frontiers in immunology · 2026Review
- Reply to 'Potential benefit of anticoagulation in Behçet syndrome'.Nature reviews. Rheumatology · 2025Article
- Atypical Pediatric-Onset Behçet's Disease Presenting With Superior Vena Cava Thrombosis in an Adolescent Male: A Case Report.Clinical case reports · 2025Article
- Potential benefit of anticoagulation in Behçet syndrome.Nature reviews. Rheumatology · 2025Article
- Pulmonary Artery Aneurysm (PAA) in Behçet's Disease Presenting With Recurrent Hemoptysis: A Case Report.Clinical case reports · 2025Article
- Arterial and venous thrombosis in systemic and monogenic vasculitis.Nature reviews. Rheumatology · 2025Review
- Novel inflammatory biomarkers for discriminating vascular involvement in Behçet's syndrome: evaluating SII, SIRI, and NPAR.Biomarkers in medicine · 2025Article
- Clinical features and chronology of clinical manifestations in Behçet's disease: a cohort of 2,615 patients.Reumatologia · 2025Article
- A rare case of Behçet's disease complicated by Budd-Chiari syndrome and perforated duodenal ulcers in a young male.Oxford medical case reports · 2024Article
- Cardiovascular Manifestations in Behçet's Disease.Yonsei medical journal · 2024Review
- Endocarditis, Intra-cardiac Thrombus, and Pulmonary Artery Aneurysm in a Patient with Behcet's Syndrome.Sisli Etfal Hastanesi tip bulteni · 2024Article
- Rare presentation of thrombosis with bleeding in Behcet's disease.BMJ case reports · 2023Article
- A case series of intracardiac thrombi and vascular involvement in pediatric Behçet's disease.Rheumatology international · 2023Article
- Treatment Options in Pediatric Behçet's Disease.Paediatric drugs · 2023Review
- Risk factors of cardiovascular involvement in patients with Behcet's disease.Journal of translational autoimmunity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively.Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 ± 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired.VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1-204) and ISs, 22 months (1-204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. A second vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments.We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.